Vigabatrin

Refractory epilepsies such as infantile spasms (IS) and complex partial seizures (CPS) can have a severe negative impact on the neurological integrity and quality of life of affected patients, in addition to drastically increasing their risk of premature mortality. Early identification of potentiall...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurotherapeutics 2007, Vol.4 (1), p.163-172
Hauptverfasser: Wheless, James W., Ramsay, R. Eugene, Collins, Stephen D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 172
container_issue 1
container_start_page 163
container_title Neurotherapeutics
container_volume 4
creator Wheless, James W.
Ramsay, R. Eugene
Collins, Stephen D.
description Refractory epilepsies such as infantile spasms (IS) and complex partial seizures (CPS) can have a severe negative impact on the neurological integrity and quality of life of affected patients, in addition to drastically increasing their risk of premature mortality. Early identification of potentially effective pharmacotherapy agents is important. Vigabatrin has been shown to be a generally well tolerated and effective antiepileptic drug (AED) in a wide variety of seizure types affecting both children and adults, particularly those with IS and CPS. A bilateral, concentric constriction of the peripheral visual field characterizes the visual field defect (VFD) associated with vigabatrin, well characterized by numerous studies. This peripheral VFD presents in 30–50% of patients with exposure of several years; however, most of these patients are asymptomatic. In well-controlled studies, the earliest onset in patients with CPS is 11 months and at 5 months in infants, with average onsets being more than 5 years and 1 year, respectively. Patients with a peripheral VFD retain an average 65° of lateral vision (normal, 90°). The fact that many patients never develop the vigabatrin-related peripheral VFD, despite long-term exposure at high doses, may support the hypothesis that the injury is an idiosyncratic adverse drug reaction (as opposed to a strict dose- or duration-dependent toxicity). Effective testing methods are available to aid in the early detection and management of the peripheral VFD. This article discusses issues of importance to clinical decision-making in the use of vigabatrin to assist the physician and patient in assessing the benefits of vigabatrin therapy and understanding the potential risks of the VFD and uncontrolled seizures.
doi_str_mv 10.1016/j.nurt.2006.11.008
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7479688</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1933721306001875</els_id><sourcerecordid>2789830711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-d663d7ca5945d097b8b8b78356af7fd9d0947efe58f069491e28b5f6810c9ea3</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMozkP_gAs3rltzm-YFIoj4ggE3g9uQ5jGmzLRj2g74702ZwcdG7iKX5Jxzbz6ELgDngIFd13kzxD4vMGY5QI6xOEJTEFxkvOTyOPWSkIwXQCZo1nU1xpQQKU7RBDhIiQmZotlbWOlK9zE0Z-jE63Xnzg_nHC0fH5b3z9ni9enl_m6RmVJAn1nGiOVGU1lSiyWvRCouCGXac29luiu5844Kj5ksJbhCVNQzAdhIp8kc3e5jt0O1cda4po96rbYxbHT8VK0O6u9LE97Vqt2p8VNMiBRwdQiI7cfgul7V7RCbtLICgKKghJU8qYq9ysS266Lz3xMAqxGfqtWIT434klElfMl0-Xu3H8uBVxLc7AUuAdoFF1VngmuMsyE60yvbhv_yvwDy7IAD</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1112253647</pqid></control><display><type>article</type><title>Vigabatrin</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Wheless, James W. ; Ramsay, R. Eugene ; Collins, Stephen D.</creator><creatorcontrib>Wheless, James W. ; Ramsay, R. Eugene ; Collins, Stephen D.</creatorcontrib><description>Refractory epilepsies such as infantile spasms (IS) and complex partial seizures (CPS) can have a severe negative impact on the neurological integrity and quality of life of affected patients, in addition to drastically increasing their risk of premature mortality. Early identification of potentially effective pharmacotherapy agents is important. Vigabatrin has been shown to be a generally well tolerated and effective antiepileptic drug (AED) in a wide variety of seizure types affecting both children and adults, particularly those with IS and CPS. A bilateral, concentric constriction of the peripheral visual field characterizes the visual field defect (VFD) associated with vigabatrin, well characterized by numerous studies. This peripheral VFD presents in 30–50% of patients with exposure of several years; however, most of these patients are asymptomatic. In well-controlled studies, the earliest onset in patients with CPS is 11 months and at 5 months in infants, with average onsets being more than 5 years and 1 year, respectively. Patients with a peripheral VFD retain an average 65° of lateral vision (normal, 90°). The fact that many patients never develop the vigabatrin-related peripheral VFD, despite long-term exposure at high doses, may support the hypothesis that the injury is an idiosyncratic adverse drug reaction (as opposed to a strict dose- or duration-dependent toxicity). Effective testing methods are available to aid in the early detection and management of the peripheral VFD. This article discusses issues of importance to clinical decision-making in the use of vigabatrin to assist the physician and patient in assessing the benefits of vigabatrin therapy and understanding the potential risks of the VFD and uncontrolled seizures.</description><identifier>ISSN: 1933-7213</identifier><identifier>ISSN: 1878-7479</identifier><identifier>EISSN: 1878-7479</identifier><identifier>DOI: 10.1016/j.nurt.2006.11.008</identifier><identifier>PMID: 17199033</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Anticonvulsants - adverse effects ; Brain - drug effects ; Clinical Trials as Topic ; complex partial seizures ; Epilepsy ; Epilepsy - drug therapy ; Humans ; infantile spasms ; Mortality ; refractory epilepsy ; Risk Assessment ; vigabatrin ; Vigabatrin - adverse effects ; Vision Disorders - chemically induced ; visual fields ; Visual Fields - drug effects ; West syndrome</subject><ispartof>Neurotherapeutics, 2007, Vol.4 (1), p.163-172</ispartof><rights>2007 The American Society for Experimental NeuroTherapeutics, Inc.</rights><rights>Springer 2007</rights><rights>The American Society for Experimental NeuroTherapeutics, Inc. 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-d663d7ca5945d097b8b8b78356af7fd9d0947efe58f069491e28b5f6810c9ea3</citedby><cites>FETCH-LOGICAL-c481t-d663d7ca5945d097b8b8b78356af7fd9d0947efe58f069491e28b5f6810c9ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479688/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479688/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17199033$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wheless, James W.</creatorcontrib><creatorcontrib>Ramsay, R. Eugene</creatorcontrib><creatorcontrib>Collins, Stephen D.</creatorcontrib><title>Vigabatrin</title><title>Neurotherapeutics</title><addtitle>Neurotherapeutics</addtitle><description>Refractory epilepsies such as infantile spasms (IS) and complex partial seizures (CPS) can have a severe negative impact on the neurological integrity and quality of life of affected patients, in addition to drastically increasing their risk of premature mortality. Early identification of potentially effective pharmacotherapy agents is important. Vigabatrin has been shown to be a generally well tolerated and effective antiepileptic drug (AED) in a wide variety of seizure types affecting both children and adults, particularly those with IS and CPS. A bilateral, concentric constriction of the peripheral visual field characterizes the visual field defect (VFD) associated with vigabatrin, well characterized by numerous studies. This peripheral VFD presents in 30–50% of patients with exposure of several years; however, most of these patients are asymptomatic. In well-controlled studies, the earliest onset in patients with CPS is 11 months and at 5 months in infants, with average onsets being more than 5 years and 1 year, respectively. Patients with a peripheral VFD retain an average 65° of lateral vision (normal, 90°). The fact that many patients never develop the vigabatrin-related peripheral VFD, despite long-term exposure at high doses, may support the hypothesis that the injury is an idiosyncratic adverse drug reaction (as opposed to a strict dose- or duration-dependent toxicity). Effective testing methods are available to aid in the early detection and management of the peripheral VFD. This article discusses issues of importance to clinical decision-making in the use of vigabatrin to assist the physician and patient in assessing the benefits of vigabatrin therapy and understanding the potential risks of the VFD and uncontrolled seizures.</description><subject>Animals</subject><subject>Anticonvulsants - adverse effects</subject><subject>Brain - drug effects</subject><subject>Clinical Trials as Topic</subject><subject>complex partial seizures</subject><subject>Epilepsy</subject><subject>Epilepsy - drug therapy</subject><subject>Humans</subject><subject>infantile spasms</subject><subject>Mortality</subject><subject>refractory epilepsy</subject><subject>Risk Assessment</subject><subject>vigabatrin</subject><subject>Vigabatrin - adverse effects</subject><subject>Vision Disorders - chemically induced</subject><subject>visual fields</subject><subject>Visual Fields - drug effects</subject><subject>West syndrome</subject><issn>1933-7213</issn><issn>1878-7479</issn><issn>1878-7479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kEtLxDAUhYMozkP_gAs3rltzm-YFIoj4ggE3g9uQ5jGmzLRj2g74702ZwcdG7iKX5Jxzbz6ELgDngIFd13kzxD4vMGY5QI6xOEJTEFxkvOTyOPWSkIwXQCZo1nU1xpQQKU7RBDhIiQmZotlbWOlK9zE0Z-jE63Xnzg_nHC0fH5b3z9ni9enl_m6RmVJAn1nGiOVGU1lSiyWvRCouCGXac29luiu5844Kj5ksJbhCVNQzAdhIp8kc3e5jt0O1cda4po96rbYxbHT8VK0O6u9LE97Vqt2p8VNMiBRwdQiI7cfgul7V7RCbtLICgKKghJU8qYq9ysS266Lz3xMAqxGfqtWIT434klElfMl0-Xu3H8uBVxLc7AUuAdoFF1VngmuMsyE60yvbhv_yvwDy7IAD</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>Wheless, James W.</creator><creator>Ramsay, R. Eugene</creator><creator>Collins, Stephen D.</creator><general>Elsevier Inc</general><general>Springer Nature B.V</general><general>Springer-Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>2007</creationdate><title>Vigabatrin</title><author>Wheless, James W. ; Ramsay, R. Eugene ; Collins, Stephen D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-d663d7ca5945d097b8b8b78356af7fd9d0947efe58f069491e28b5f6810c9ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Anticonvulsants - adverse effects</topic><topic>Brain - drug effects</topic><topic>Clinical Trials as Topic</topic><topic>complex partial seizures</topic><topic>Epilepsy</topic><topic>Epilepsy - drug therapy</topic><topic>Humans</topic><topic>infantile spasms</topic><topic>Mortality</topic><topic>refractory epilepsy</topic><topic>Risk Assessment</topic><topic>vigabatrin</topic><topic>Vigabatrin - adverse effects</topic><topic>Vision Disorders - chemically induced</topic><topic>visual fields</topic><topic>Visual Fields - drug effects</topic><topic>West syndrome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wheless, James W.</creatorcontrib><creatorcontrib>Ramsay, R. Eugene</creatorcontrib><creatorcontrib>Collins, Stephen D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neurotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wheless, James W.</au><au>Ramsay, R. Eugene</au><au>Collins, Stephen D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vigabatrin</atitle><jtitle>Neurotherapeutics</jtitle><addtitle>Neurotherapeutics</addtitle><date>2007</date><risdate>2007</risdate><volume>4</volume><issue>1</issue><spage>163</spage><epage>172</epage><pages>163-172</pages><issn>1933-7213</issn><issn>1878-7479</issn><eissn>1878-7479</eissn><abstract>Refractory epilepsies such as infantile spasms (IS) and complex partial seizures (CPS) can have a severe negative impact on the neurological integrity and quality of life of affected patients, in addition to drastically increasing their risk of premature mortality. Early identification of potentially effective pharmacotherapy agents is important. Vigabatrin has been shown to be a generally well tolerated and effective antiepileptic drug (AED) in a wide variety of seizure types affecting both children and adults, particularly those with IS and CPS. A bilateral, concentric constriction of the peripheral visual field characterizes the visual field defect (VFD) associated with vigabatrin, well characterized by numerous studies. This peripheral VFD presents in 30–50% of patients with exposure of several years; however, most of these patients are asymptomatic. In well-controlled studies, the earliest onset in patients with CPS is 11 months and at 5 months in infants, with average onsets being more than 5 years and 1 year, respectively. Patients with a peripheral VFD retain an average 65° of lateral vision (normal, 90°). The fact that many patients never develop the vigabatrin-related peripheral VFD, despite long-term exposure at high doses, may support the hypothesis that the injury is an idiosyncratic adverse drug reaction (as opposed to a strict dose- or duration-dependent toxicity). Effective testing methods are available to aid in the early detection and management of the peripheral VFD. This article discusses issues of importance to clinical decision-making in the use of vigabatrin to assist the physician and patient in assessing the benefits of vigabatrin therapy and understanding the potential risks of the VFD and uncontrolled seizures.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>17199033</pmid><doi>10.1016/j.nurt.2006.11.008</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1933-7213
ispartof Neurotherapeutics, 2007, Vol.4 (1), p.163-172
issn 1933-7213
1878-7479
1878-7479
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7479688
source MEDLINE; SpringerLink Journals; PubMed Central; Alma/SFX Local Collection
subjects Animals
Anticonvulsants - adverse effects
Brain - drug effects
Clinical Trials as Topic
complex partial seizures
Epilepsy
Epilepsy - drug therapy
Humans
infantile spasms
Mortality
refractory epilepsy
Risk Assessment
vigabatrin
Vigabatrin - adverse effects
Vision Disorders - chemically induced
visual fields
Visual Fields - drug effects
West syndrome
title Vigabatrin
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A33%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vigabatrin&rft.jtitle=Neurotherapeutics&rft.au=Wheless,%20James%20W.&rft.date=2007&rft.volume=4&rft.issue=1&rft.spage=163&rft.epage=172&rft.pages=163-172&rft.issn=1933-7213&rft.eissn=1878-7479&rft_id=info:doi/10.1016/j.nurt.2006.11.008&rft_dat=%3Cproquest_pubme%3E2789830711%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1112253647&rft_id=info:pmid/17199033&rft_els_id=S1933721306001875&rfr_iscdi=true